Florida SB 1768: What Biologics Practitioners Need to Know
Stem Nova NetworkFlorida became one of the first states to create a formal framework for non-FDA-approved stem cell biologics when Senate Bill 1768 took effect on July 1, 2025. The law passed 37–0 in the Senate and 112–0 in the House, signaling broad legislative support for giving licensed physicians a structured pathway to offer certain biologic procedures. For practitioners sourcing regenerative biologics, understanding SB 1768 is now a baseline requirement for operating in the Florida market.
What SB 1768 Actually Does
SB 1768 permits Florida-licensed physicians (MDs under Chapter 458 and DOs under Chapter 459) to perform non-FDA-approved biologic procedures using stem cells or other human cells and tissues, within defined scope-of-practice boundaries. The law limits these procedures to three categories: orthopedics, wound care, and pain management.
This is not a blanket authorization. The law establishes a tightly defined corridor with specific requirements for who can perform procedures, what products may be used, and how patients must be informed. Practitioners operating outside these boundaries remain subject to existing state and federal regulations.
Who Qualifies
Only physicians licensed under Florida Chapter 458 (MD) or Chapter 459 (DO) may perform procedures under SB 1768. The law does not extend to chiropractors, naturopaths, or independent mid-level practitioners operating outside physician supervision.
Sourcing Requirements Under SB 1768
The sourcing provisions are among the most significant aspects of SB 1768 for practitioners evaluating biologics suppliers. The law requires that biologic products used under its authority come from facilities that meet three specific criteria:
These sourcing requirements reinforce the importance of working with suppliers who maintain verifiable documentation at every stage of manufacturing. Practitioners should request and retain Certificates of Analysis (COAs), accreditation documentation, and viability reports as part of their compliance files.
Tissue Sources and Limitations
SB 1768 emphasizes afterbirth placental and perinatal tissue sources, as well as other ethically obtained human tissue. The law contains one absolute prohibition: cells derived from a fetus or embryo after an abortion may not be used. Using such cells constitutes a third-degree felony under the statute.
Birth tissue products—including those derived from umbilical cord and Wharton's jelly—align with the tissue sources described in the law. Practitioners sourcing these materials should verify that their supplier can document the ethical origin and chain of custody for every product lot.
Informed Consent and Advertising Requirements
Practitioners performing procedures under SB 1768 must obtain documented informed consent from each patient. The consent must address the nature of the procedure, its lack of FDA approval, associated risks, and available alternatives—including the option of no intervention. Patients must also be encouraged to consult their primary care provider.
Advertising for procedures performed under SB 1768 must include a conspicuous notice that the biologics used are not FDA-approved. This notice must appear in type at least as large as the largest font used elsewhere in the advertisement.
Scope Limitations Practitioners Should Understand
The boundaries of SB 1768 are as important as its permissions. Several key limitations shape how practitioners can operate under this framework:
| Provision | What It Means |
|---|---|
| Indication-Specific | Procedures must fall within orthopedics, wound care, or pain management |
| Localized Use Only | Systemic administration (such as IV infusion) is not permitted under SB 1768 |
| Physician-Only | Only MDs and DOs licensed in Florida may perform these procedures |
| State-Level Only | SB 1768 creates a state framework. Federal requirements, including FDA regulations, remain fully in effect |
This last point deserves emphasis. SB 1768 is a state law. It does not override the Federal Food, Drug, and Cosmetic Act or any other federal regulation. Products that cross state lines remain subject to federal jurisdiction, and products classified as drugs or biologics under Section 351 of the Public Health Service Act still require appropriate federal authorization.
What This Means for Biologics Sourcing
For practitioners evaluating biologics suppliers—whether operating under SB 1768 or in any other state—the Florida law highlights the documentation and quality standards that responsible sourcing requires. The core principles SB 1768 codifies are the same principles that inform sound sourcing decisions nationwide:
- Work with FDA-registered facilities
- Verify third-party accreditation (AATB, AABB, or equivalent)
- Request and retain post-thaw viability reports and Certificates of Analysis
- Confirm the ethical sourcing and documented chain of custody for all tissue products
- Maintain informed consent documentation for every patient interaction
Regardless of your state, these practices represent the standard of documentation that protects both the practitioner and the patient. Florida has formalized them into statute. Other states may follow.
Source Biologics from an FDA-Registered, cGTP-Compliant Facility
Stem Nova Network provides dual-lab COA verification, AATB-accredited sourcing for hUCT-MSC products, and full documentation for every lot shipped.
Apply for a Wholesale Account → Contact Our TeamFrequently Asked Questions
What is Florida SB 1768?
SB 1768 is a Florida state law, effective July 1, 2025, that creates a regulatory framework for licensed MDs and DOs to perform certain non-FDA-approved stem cell biologic procedures. It applies to orthopedic, wound care, and pain management indications and requires specific sourcing, consent, and disclosure standards.
Does SB 1768 mean stem cell products are now FDA-approved in Florida?
No. SB 1768 is a state-level law that permits certain procedures under defined conditions. It does not grant FDA approval to any product. Federal regulations, including FDA requirements, remain fully in effect regardless of state legislation.
Who can perform procedures under SB 1768?
Only physicians licensed under Florida Chapter 458 (MD) or Chapter 459 (DO). The law does not extend to chiropractors, naturopaths, nurse practitioners, or physician assistants operating independently.
What sourcing requirements does SB 1768 impose?
Biologic products must come from an FDA-registered facility with recognized accreditation (such as AATB or AABB). The supplier must also provide a post-thaw viability report for each treatment lot.
Does SB 1768 apply to topical cosmetic exosome products?
SB 1768 specifically addresses stem cell procedures for orthopedic, wound care, and pain management indications. Topical cosmetic exosome applications operate under a different regulatory framework and are not specifically addressed by this statute.
Can practitioners in other states use SB 1768 as a model?
While practitioners in other states cannot operate under Florida's law, SB 1768 reflects sourcing and documentation standards—FDA-registered facilities, accreditation verification, viability reporting, and informed consent—that represent sound practice in any state.
Related Resources
- AATB Accreditation, Federal Compliance, and the State-by-State Legal Landscape for Stem Cell Biologics in 2026
- UCT-MSC Biologics: What Licensed Physicians Need to Know About Sourcing and Documentation
- 7 Red Flags to Watch For When Sourcing Exosomes & Stem Cells
- How to Read and Evaluate an Exosome Certificate of Analysis (COA)
